dagil-y 1

1. Immunogenic Properties and Safety of a Quadrivalent Inactivated Subunit Adjuvanted Influenza Vaccine in Adults Aged 18 to 85 Years at the End of the COVID-19 Pandemic in the 2022–2023 Season
2. Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates
1